The Company’s advanced AI-based integrated computational LANCE platform explores immune cell activity and metabolic function, a distinct approach that has verified two novel pathways currently in clinical development: LANCL2 and NLRX1. Activation of the LANCL2 pathway amplifies the immunosuppressive functions of T regulatory cells while decreasing production of inflammatory cytokines such as TNF-alpha. NLRX1, a second pathway discovered by Landos, provides a mechanism for modulating immune functions to complement or act in combination with other related treatments.
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. BT-11, the Company’s lead asset, is completing a Phase 2 trial in mild to moderate ulcerative colitis (UC) in the U.S. Europe and Russia, with plans to initiate a Phase 2 trial of BT-11 in moderate to severe Crohn’s disease (CD). BT-11 is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.